ArticleDigestive diseases and sciences2026
Racial Disparities in Clinical and Cardiometabolic Outcomes Among Patients with Alcohol-Associated Liver Disease.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe assess racial disparities in the prevalence and incidence of clinical outcomes in alcohol-associated liver disease (ALD) in a diverse US population.
methodsThis is a retrospective multicenter study on patients aged 18-80 years with ALD in the Banner Health System from 2012 to 2024. Patients with major adverse liver outcomes (MALO) (ascites, hepatic encephalopathy, hepatocellular carcinoma, esophageal variceal bleeding) at baseline were excluded. Primary outcomes included mortality and the incidence of MALO, cardiovascular diseases (CVD) (coronary artery disease (CAD), congestive heart failure (CHF), cerebrovascular accidents (CVA), peripheral artery disease), type II diabetes mellitus (DM), cirrhosis, major adverse cardiovascular events (MACE) (CAD, CHF, CVA, mortality), and all-cause cancer. Competing risk and Cox proportional hazard regression analyses were used for outcome modeling.
resultsThe cohort included 16,693 patients with ALD. The median age was 50.3 and 67.8% were male. The racial distribution was 66.7% Non-Hispanic White (NHW), 0.4% Asian/Pacific Islander, 3.2% Black, 17.9% Hispanic, and 11.8% Native American/Alaskan (NA). Compared to NHW patients, NA patients had higher mortality (aHR: 1.85, 95% CI: 1.50-2.27) and higher incidence of MALO (aHR: 1.19, 95% CI: 1.04-1.37), cirrhosis (aHR: 1.51, 95% CI: 1.28-1.79) and MACE (aHR: 1.38, 95% CI: 1.20-1.59).
conclusionNA patients with ALD had higher mortality and incidence of adverse clinical outcomes compared to NHW. Further research is warranted to explore these disparities and develop tailored interventions to improve outcomes.
Indexed as
Identifiers
42142226What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.